• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300636.SZ
Share

Jiangxi Synergy Pharmaceutical Co., Ltd. Stocks

CN¥ 6.67Last Updated 14.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 413.38M

CN¥ 6.67
Key Takeaways

Risk factor

Vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Somewhat favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Yichun, People's Republic of China, Jiangxi Synergy Pharmaceutical Co., Ltd. was established in 2004. The company specializes in the global production and sale of active pharmaceutical ingredients (APIs), as well as liquid crystal compounds and various chemical intermediates.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 300636.SZ is 8.50 and suggests 27.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 18:30

Revolut Will Participate in Testing the Digital Euro

14.07.2026 18:12

Oil at $87, Houthi attacks, strikes on UAE tankers: What’s happening in the Middle East?

14.07.2026 17:48

Consumer inflation in the U.S. turned out to be much lower than expected

14.07.2026 17:40

Nebius closed a $1 billion deal with a startup founded by former Google AI developers

14.07.2026 17:25

SpaceX Lost More Than $800 Billion in Market Value in a Month: Shares Are Close to Their IPO Price

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026